Abstract
Patient-reported outcomes from the BESPOKE CRC study
Journal of clinical oncology, Vol.42(3_suppl), pp.54-54
01/20/2024
DOI: 10.1200/JCO.2024.42.3_suppl.54
Abstract
54 Background: BESPOKE CRC is a multicenter, prospective, observational study that investigates the clinical utility of ctDNA for optimal use of adjuvant chemotherapy and early detection of recurrence in patients (pts) with surgically resected CRC. The perceived utility and impact ctDNA testing results have on pts’ anxiety about cancer recurrence is not entirely known. Herein, we formally report perceived utility and dimensions of well being that pts getting ctDNA testing reported. Methods: A total of 1792 pts with stages I–IV CRC were enrolled and followed for a median of 16.6 months with serial ctDNA analysis using a personalized, tumor-informed assay (SignateraTM, Natera, Inc.). An optional survey was collected at the time of enrollment and at 4 and 12 weeks (w), and 6, 12, 18 and 24 months (m) post-resection. The survey included: (1) Hospital Anxiety and Depression Scale (HADS), (2) Fear of Cancer Recurrence (FCR-4), (3) National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index-19 items (NCCN-FACT FCSI-19 version 2), and (4) ctDNA utility questionnaire (perceived utility and impact of ctDNA test results on pts’ anxiety about recurrence). The score ranges were: HADS: 0 (no) to 21 (valid) anxiety/depression; FCR-4: 0 (minimal) to 20 (maximum) fear of cancer recurrence; FCSI-19: 0 (severely symptomatic) to 76 (asymptomatic); ctDNA utility: 5=strongly agree, 4=agree, 3=neutral, 2=disagree, 1=strongly disagree. Results: A total of 1129/1123/1125/1136 responses from 414/413/413/418 pts were received for HADS/FCR-4/FCSI-19/ctDNA questionnaires, respectively. When compared between ctDNA-negative and -positive pts, FCR-4 and FCSI-19 surveys revealed marginal numerical differences in pts’ mean FCR-4/FCSI-19 scores, although statistically significant (FCR-4: 9.1 vs 10.4, p<0.01; FCSI-19: 58.6 vs. 53.8, p<0.001). No significant differences in the anxiety and depression scores (HADS) were found between ctDNA-negative and -positive pts. Irrespective of the ctDNA result, 89% of the responders said they valued the additional information received from ctDNA results, and 86% said they would continue using the ctDNA test to monitor cancer. Regardless of the ctDNA results, 74% of pts reported feeling they were receiving the right treatment after receiving their results. ctDNA results reduced anxiety about cancer recurrence in 62% of pts. Notably, ctDNA-negative pts felt less anxious of recurrence compared to ctDNA-positive pts (average score 4.01 vs 3.57, p<0.0001). Conclusions: Most responders valued the information they received through the personalized, tumor-informed ctDNA tests and would continue ctDNA testing. Pts with ctDNA positive results felt slightly more anxious about CRC recurrence, while ctDNA-negative pts reported reduced anxiety levels. Our results for the first time show the important dimensions of pt well being and perceived utility of ctDNA testing in pts with CRC. Clinical trial information: NCT04264702 .
Details
- Title: Subtitle
- Patient-reported outcomes from the BESPOKE CRC study
- Creators
- Pashtoon Murtaza Kasi - NewYork–Presbyterian HospitalSamuel Rivero - NateraVasily N. Aushev - NateraNathan Langer - Virginia Cancer InstituteChristopher Gene Wang - Pediatric Nephrology of AlabamaTimothy Lewis Cannon - Virginia Cancer InstituteLyudmyla Derby Berim - Rutgers, The State University of New JerseyTrevor Feinstein - Piedmont Cancer InstituteAxel Grothey - West Cancer CenterJoseph William McCollom - Parkview HealthSujith R. Kalmadi - Ironwood PharmaceuticalsAhmed Zakari - Florida Hospital Cancer InstituteFarshid Dayyani - University of California, IrvineDonald Gravenor - New England Baptist HospitalJanelle Marie Meyer - Oncology SpecialistsSaima Sharif - University of IowaAdham A Jurdi - NateraMinetta C. Liu - NateraAlexey Aleshin - NateraScott Kopetz - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.42(3_suppl), pp.54-54
- DOI
- 10.1200/JCO.2024.42.3_suppl.54
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: None.
- Language
- English
- Date published
- 01/20/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984554855702771
Metrics
1 Record Views